All manufacturers of anti-diabetic drugs have issued press releases on their Q2 earnings. Novo Nordisk on August 9th and Eli Lilly on July 30th. And the 79th Scientific Sessions of the American Diabetes Association took place June 7-11, so a look at the changes in the diabetes landscape is due. Worldwide sale of insulin continues …
Continue reading “Recent developments in the diabetes landscape halfway into 2019”
On August 20th Pandora issued a press release regarding Q2 earnings. The share price subsequently surged; especially following purchases by the CEO and CFO. It seems the absence of bad news is good news in the case of Pandora at the current point of the restructuring plan and at current price levels. Below some important …
Kraft Heinz issued a press release on its Q2 earnings on August 8th and has with delay filed its 10Qs for Q1 and Q2 on August 14th. This article will cover a) the goodwill and asset impairment losses, b) the compression of profit margins, c) the debt and bond grade situation, d) the dividend and …
Teva Pharmaceuticals issued a press release on their Q2 earnings on August 7th. Below are excerpts from the earnings call with CEO Kåre Schultz and outgoing CFO Michael McClellan and relevant figures and slides. Further below the CGRP migraine drugs Ajovy® from Teva, Aimovig® from Amgen and Emgality® from Lilly are discussed. The legacy litigations …
General Mills ($GIS) issued a press release on their quarterly earnings. Sale of yogurt in the US has stabilised after several consecutive quarters of market share losses to Chobani. Sales in the pet segment are up by 11% on an annual basis (and 38% on a quarterly YoY basis) following the acquisition of Blue Buffalo. …
Continue reading “General Mills US yogurt sales stable but snacks down 5%”
The jewelry company Pandora has issued a press release regarding their quarterly results with the comments below from the new CEO and the CFO. Alexander Lacik, CEO: “I’m very excited to join Pandora. We have some very strong fundamentals in terms of a world-class supply chain, a strong product proposition as well as a deep …
Continue reading “The Pandora turnaround postponed until 2020?”
Press releases regarding first quarter results have been issued from diabetes competitors Novo Nordisk, Eli Lilly, Sanofi and others. Four of the main antidiabetic drug types manufactured by these pharmaceutical companies are insulin, GLP-1 receptor agonists, SGLT2 inhibitors (gliflozins) and DPP4 inhibitors (gliptins). The development in each of the four drug categories is covered in …
Continue reading “Diabetes developments in the first quarter of 2019”
Teva reported on their first quarter results and issued the following press release with the following headlines and statements from the CEO: – Revenues of $4.3 billion – GAAP diluted loss per share of $0.10 – Non-GAAP diluted EPS of $0.60 – Free cash flow of $360 million – Spend base reduction of $2.5 billion …
Apple issued a press release about their quarterly results with the headline “Services Revenue Reaches New All-Time High of $11.5 Billion”. “Our March quarter results show the continued strength of our installed base of over 1.4 billion active devices, as we set an all-time record for Services, and the strong momentum of our Wearables, Home …
Today Pandora released their annual earnings. The self explanatory figures below summarise the earnings, the margins, the ROIC and the growth for the recent comparable quarters and for the previous TTM periods by product segment and by geographic segment. Revenue and earnings Margins ROIC By product segment By geographic segment Programme NOW In November Programme …